Navigation Links
Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
Date:3/17/2009

Company Plans to Advance to Phase Three Trials

FRAZER, Pa., March 17 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced positive results from a phase two clinical trial of NUVIGIL(R) (armodafinil) Tablets [C-IV] as adjunctive therapy for treating major depressive disorder in adults with bipolar I disorder. An estimated two million American adults are affected by bipolar I disorder, which is characterized by fluctuations between extreme highs (manic) and lows (depressed) in mood. People with bipolar disorders cycle between periods of manic or depressive mood and typically spend more time in the depressed phase of the illness.

The eight-week, double-blind, placebo-controlled study evaluated the efficacy and safety of NUVIGIL (150 mg/day) as an adjunctive therapy to mood stabilizers in 257 patients with bipolar I disorder, who experienced a major depressive episode that was not completely managed by their other treatments. Patients in the study taking NUVIGIL as adjunctive therapy showed improvement of depressive symptoms (p=0.042) as measured on the primary endpoint - the 30-Item Inventory of Depressive Symptomatology, Clinician-Rated (IDS-C30) scale. The IDS-C30 scale is an instrument used to evaluate depressive episodes and associated symptoms. The results of this study will be presented at an upcoming medical meeting.

"We are encouraged that the results of this study point toward the potential utility of NUVIGIL in managing the depressive episodes in bipolar I disorder," said Dr. Lesley Russell, Executive Vice President and Chief Medical Officer at Cephalon. "We now plan to conduct phase three trials to further evaluate the efficacy and safety of NUVIGIL in this patient population."

NUVIGIL was generally well-tolerat
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
2. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
7. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
8. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
9. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
10. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
11. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, ... a vegetable-glycol solution for use in portable vaporizers, ... the active ingredients in cannabis, cannabidiol offers consumers ... vaporizer devices, and other vaporizer technology. ... Cannabis naturally contains 483 different compounds which are ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
(Date:7/11/2014)... 2014 The consumer marketing playbook and ... sectors to better identify winning tools and techniques. ... with and understand consumers, as new technologies are ... purchasing decisions. According to recent ... area where organizations can observe a deep pool ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
... TUCSON, Ariz., April 26, 2012  SynCardia Systems, Inc. ( ... FDA, Health Canada and CE (Europe) approved Total Artificial ... two-time Olympian, Gaetano "Gates" Orlando, has become the first ... SynCardia temporary Total Artificial Heart . The 49-year-old, who ...
... (Nasdaq: MYL ) today announced its financial results for ... Results , Adjusted diluted EPS of $0.52 for the ... same prior year period, an increase of 18%; , ... March 31, 2012 compared to $1.45 billion for the same prior ...
Cached Medicine Technology:Retired Pro Hockey Player 1st to Receive Total Artificial Heart in Upstate New York 2Retired Pro Hockey Player 1st to Receive Total Artificial Heart in Upstate New York 3Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 2Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 3Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 4Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 5Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 6Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 7Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 8Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 9Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 10Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 11Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 12Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 13
(Date:7/13/2014)... Seattle, WA (PRWEB) July 13, 2014 According ... Vkool.com, this is a step by step guide on what ... impairment easily and quickly. Vkool writes in its review ... what foods to eat to revitalize their kidney health. Vkool ... book can help people reverse their damaged kidney functions naturally. ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Wright & ... trial has been scheduled in July of 2015, in ... Lipitor lawsuits are in the discovery process in ... M. Gergel is presiding over the multidistrict litigation (MDL). ... on behalf of individuals who allege that they took ...
(Date:7/13/2014)... 13, 2014 A Xarelto lawsuit ... LLC to provide consumers with the most current information ... of the blood-thinning medication, as well as the ... courts around the country. The law firm is now ... suffered from life-threatening internal bleeding and related complications while ...
(Date:7/13/2014)... July 13, 2014 Celebrity fitness trainer ... formed a promotional partnership with Aqua Health Labs for ... Omega-3 EPA supplement . The collaboration was recently announced ... fitness trainer , actor, model, and a two ... for A-List celebrities, he has prepared stars including Demi ...
(Date:7/13/2014)... ECS is being founded by ... of a special needs child, I have become keenly ... for contemporary special education resources and evidence-based instruction. Emerald ... and families in the Seattle metro area that are ... education. We welcome the opportunity to serve our community ...
Breaking Medicine News(10 mins):Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:New Private School, Emerald City School, Founded in Downtown Seattle Now Accepting 1st to 6th Grade Students Who Learn Differently 2
... that instruction alone is no guarantee , , MONDAY, March ... lessons doesn,t increase their risk of drowning, says a ... that swimming lessons could actually increase drowning risk by ... in and around water. , U.S. government researchers ...
... Heartland report uncovers staggering shortfall in meals needed to ... to start filling the gapSAINT PAUL, Minn., March 2 ... the Upper Midwest,s leading voice on hunger relief, today ... every year--the equivalent of those in need going to ...
... Seattle, WA; Ogden, UT March 2, 2009) ... States show that educational materials aimed at preventing shaken ... crying, which is the number one trigger for people ... mothers to warn babysitters about shaken baby syndrome and ...
... abortion corruption; OR urges supporters to immediately contact ... March 2 Operation Rescue has vowed to ... as Secretary of Health and Human Services with ... a unified voice in the pro-life/pro-family community against ...
... says, , , MONDAY, March 2 (HealthDay News) -- Elderly women who ... normal to break a hip within a year after the arm ... efforts to prevent both types of fractures. , "There have ... fractures and hip fractures, but we wanted to determine when that ...
... drugs designed to starve tumors of their blood supply ... more invasive cancer growthsometimes with a higher incidence of ... research clarifies similar findings in other animal studies and ... number of clinical trials with cancer patients. , "People ...
Cached Medicine News:Health News:Swimming Lessons Don't Increase Drowning Risk, Study Says 2Health News:Missing: 125 Million Meals for Low-Income Minnesotans 2Health News:Missing: 125 Million Meals for Low-Income Minnesotans 3Health News:Missing: 125 Million Meals for Low-Income Minnesotans 4Health News:Educational materials increase knowledge and behaviors important for preventing shaken baby syndrome 2Health News:Educational materials increase knowledge and behaviors important for preventing shaken baby syndrome 3Health News:Operation Rescue Launches Opposition to Gov. Sebelius' Confirmation as HHS Secretary 2Health News:Operation Rescue Launches Opposition to Gov. Sebelius' Confirmation as HHS Secretary 3Health News:In Elderly Women, Hip Fractures Often Follow Arm Breaks 2Health News:Study sheds light on angiogenesis inhibitors, points to limitations, solutions 2Health News:Study sheds light on angiogenesis inhibitors, points to limitations, solutions 3Health News:Study sheds light on angiogenesis inhibitors, points to limitations, solutions 4
Product includes all 15 Lexi-Comps databases. Includes Lexi-drugs, the official reference of the American Pharmacists Association and the National Professional Society of Pharmacists....
... Knife with BD Xstar Blade includes a ... the blade in prodedure and handling. ... a grind-less process for manufacturing surgical blades. ... and consistency. The arch style, single-bevel ...
Electric high speed system....
The Durafuge 100 spins swing-out rotors at 4000 rpm and fixed-angle rotors at up to 6300 rpm....
Medicine Products: